% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Schubert:154279,
author = {N. A. Schubert and C. D. Lowery and G. Bergthold and J.
Koster and T. F. Eleveld and A. Rodríguez and D. T. W.
Jones$^*$ and G. Vassal and L. F. Stancato and S. M.
Pfister$^*$ and H. Heidelberg University Hospital and H. N.
Caron and J. J. Molenaar},
othercontributors = {H. German Cancer Research Center and H. German Cancer
Research Center},
title = {{S}ystematic target actionability reviews of preclinical
proof-of-concept papers to match targeted drugs to
paediatric cancers.},
journal = {European journal of cancer},
volume = {130},
issn = {0959-8049},
address = {Amsterdam [u.a.]},
publisher = {Elsevier},
reportid = {DKFZ-2020-00706},
pages = {168 - 181},
year = {2020},
abstract = {Children with cancer are in urgent need of new therapies,
as approximately $25\%$ of patients experience a relapse and
$20\%$ succumb to their disease. Moreover, the majority of
survivors suffer from clinically relevant health problems.
Repurposing of targeted agents developed for adult
indications could provide novel therapeutic options for
paediatric cancer patients. To prioritise targeted drugs for
paediatric clinical development, we applied a systematic
review methodology to develop a Target Actionability Review
(TAR) strategy. These TARs assess the strength and
completeness of published preclinical proof-of-concept (PoC)
data by structured critical appraisal of and summarising the
available scientific literature for a specific target
(pathway) and the associated drugs in paediatric tumours.A
sensitive literature search in PubMed was performed and
relevant papers were identified. For each paper, the
individual experimental findings were extracted, marked for
paediatric tumour type and categorised into nine separate
PoC data modules. Each experimental finding was scored for
experimental outcome and quality independently by two
reviewers; discrepancies were assessed by a third reviewer
and resolved by adjudication. Scores corresponding to one
PoC module were merged for each tumour type and visualised
in a heat map matrix in the publicly available R2 data
portal [r2.amc.nl].To test our TAR methodology, we conducted
a pilot study on MDM2 and TP53. The heat map generated from
analysis of 161 publications provides a rationale to support
drug development in specific paediatric solid and brain
tumour types. Furthermore, our review highlights tumour
types where preclinical data are incomplete or lacking and
for which additional preclinical testing is advisable.},
subtyp = {Review Article},
cin = {B360 / B062},
ddc = {610},
cid = {I:(DE-He78)B360-20160331 / I:(DE-He78)B062-20160331},
pnm = {312 - Functional and structural genomics (POF3-312)},
pid = {G:(DE-HGF)POF3-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:32224415},
doi = {10.1016/j.ejca.2020.01.027},
url = {https://inrepo02.dkfz.de/record/154279},
}